GLP-1 and heart rate: what the Wegovy, Ozempic, Mounjaro, Zepbound and Foundayo labels report about resting heart rate increases

A side effect that rarely makes the headlines

People who start a GLP-1 medicine expect nausea and appetite changes. A faster resting pulse is less talked about, and it sometimes surprises people who wear a fitness tracker and notice their morning heart rate drift up. The FDA-approved labels do address it, but each manufacturer reports it in a different place and in different units of detail. This article lays the numbers side by side so you can see what is actually in the labels, and also what is not.

We reviewed the current prescribing information for Wegovy label (injection and tablets, revised 06/2026), the Ozempic label, the Mounjaro label (revised 08/2026), the Zepbound label (revised 08/2026) and the Foundayo label (revised 07/2026), and checked each on 12 October 2026. We quote only figures that appear in those documents and attribute them to the label that reports them.

What each label reports

Medicine	Where it appears	Reported change in resting heart rate	Instruction
Wegovy injection	Section 5.9 (Warnings and Precautions) and 6.1	Mean increases of 1 to 4 bpm versus placebo in adult weight-reduction trials	If patients experience a sustained increase in resting heart rate, discontinue Wegovy.
Wegovy tablets	Section 5.9	Label states treatment was associated with increases in resting heart rate	Same instruction: discontinue if the increase is sustained.
Ozempic	Section 6.1 (adverse reactions); no separate Section 5 warning	Ozempic 0.5 mg and 1 mg: mean increase of 2 to 3 bpm in placebo-controlled trials	None specific to heart rate in the passage reviewed.
Mounjaro	Section 6.1	Mean increase of 2 to 4 bpm, with a 1 bpm mean increase on placebo	None specific to heart rate in the passage reviewed.
Zepbound	Section 6.1	Mean increase of 1 to 3 bpm in pooled Studies 1 and 2; the label reports no increase on placebo	None specific to heart rate in the passage reviewed.
Foundayo	Section 6.1 (tachycardia, under other adverse reactions)	Pooled Trials 1 and 2: mean increase of 4 to 5 bpm from baseline versus 0.5 bpm with placebo	None specific to heart rate in the passage reviewed.

Notice that the numbers are small averages. A mean increase of 2 to 3 bpm across a trial population is a very different thing from a particular person’s pulse doubling, and the label figures say nothing about how individual responses are distributed except where we quote it below. Also notice that the labels count different things: some report a mean change from baseline, others a mean difference from placebo. We have used each label’s own phrasing rather than calling the figures equivalent.

Wegovy: the only label with a formal warning

The Wegovy label is the most detailed. Section 5.9 says that Wegovy was associated with increases in resting heart rate, and it reports mean increases of 1 to 4 bpm in adults treated with the injection versus placebo in weight-reduction trials. It also describes the spread. The label reports that maximum changes at any visit of 10 to 19 bpm occurred in 41% of Wegovy-treated adults versus 34% on placebo, and changes of 20 bpm or more in 26% versus 16%. In pediatric patients with a normal baseline heart rate, maximum changes of 20 bpm or more were seen in 54% of Wegovy patients versus 39% on placebo. These are the label’s own percentages, and they come from adult and pediatric weight-reduction trials that the section does not name.

The instruction is the part to remember: if a patient has a sustained increase in resting heart rate, discontinue Wegovy. The label does not define “sustained” with a number of days or a threshold in the passage we reviewed, and we will not invent one. In practice that is a conversation with the prescriber, ideally with a few days of readings from a home monitor or watch. For the pediatric context, see our guide on GLP-1 use in children and teens.

Ozempic, Mounjaro, Zepbound: adverse-reaction tables, not warnings

The tirzepatide and Ozempic labels place heart rate in the adverse reaction section. The Ozempic label states that in placebo-controlled trials the 0.5 mg and 1 mg doses resulted in a mean increase of 2 to 3 bpm, and it has no separate heart-rate warning. The Mounjaro label gives a mean increase of 2 to 4 bpm with 1 bpm on placebo, and adds a more specific figure: sinus tachycardia, defined in the label as a rise of at least 15 bpm from baseline, was reported in 4.3% of placebo patients and in 4.6%, 5.9% and 10% of patients taking Mounjaro 5 mg, 10 mg and 15 mg respectively. That pattern, where higher doses show a higher share of larger rises, is what the label table shows; we read it as descriptive rather than as a guarantee about any dose.

The Zepbound label reports a mean increase of 1 to 3 bpm in its pooled weight-reduction studies, with no increase on placebo, and does not report sinus tachycardia rates in the section we reviewed. The two tirzepatide labels share an active ingredient but not the same trial populations, which is why their numbers differ.

Foundayo: the oral tablet with the largest reported average

The Foundayo label lists tachycardia under other adverse reactions and reports, in a pool of its Trials 1 and 2, a mean increase in heart rate of 4 to 5 bpm from baseline compared with 0.5 bpm for placebo. It is the highest average among the labels in this article, but it comes from a different molecule, a different study population and a different statistical frame, so we do not say Foundayo “raises heart rate more” than the others. The honest reading is narrower: each label reports that, on average, heart rate rose by a few beats per minute. Our comparison of Foundayo and the Wegovy pill covers other differences between the two tablets.

Why this matters, and what the labels do not claim

The labels report the heart-rate finding as an observation. They do not, in the passages we reviewed, state a mechanism, and we will not offer one as fact. They also do not tell patients to check their pulse daily or to change their dose because of a small rise. What they do say, for Wegovy, is to stop if the rise is sustained. For everything else, the safe reading is that the effect is real on average, small, and worth mentioning to a clinician if you have a history of palpitations, an irregular heartbeat or heart disease, or if you take other medicines that affect heart rate.

Heart rate can also change for reasons that have nothing to do with the drug. Dehydration from vomiting or diarrhea can quicken the pulse, and our article on dehydration and acute kidney injury explains the volume-depletion warning the labels carry. Rapid weight loss, changes in fitness, caffeine, alcohol and illness can all shift a resting pulse. A trend in a tracker is a prompt for a conversation, not a diagnosis.

A practical way to track it

1. Take a baseline before the first dose. Resting readings on several mornings give you something to compare against.
2. Measure the same way each time. Seated, rested, at a similar time of day, because the labels’ averages are only meaningful against a stable baseline.
3. Note dose changes. The Mounjaro table shows larger rises more often at the higher doses, so a change after an escalation step is worth writing down.
4. Watch for symptoms, not just the number. Palpitations, dizziness, chest discomfort or fainting warrant prompt medical advice regardless of what a device reads.
5. Bring the log to your prescriber. For Wegovy in particular, the label ties the stop decision to a sustained increase.

If you are taking other medicines, the label sections on interactions are worth a read; see oral medicine absorption and drug interactions and hypoglycemia with insulin and sulfonylureas. A fast heartbeat can accompany low blood sugar, which is one reason to know which of your medicines carry that risk.

Compounded products

These figures come from FDA-approved products. Compounded semaglutide and tirzepatide are not FDA-approved and have no label of their own, so there is no label figure for them. We have deliberately left prices out of this article because the topic is safety data.

Common mistakes

• Reading the averages as individual predictions. A 2 to 3 bpm mean change says little about one person.
• Comparing across labels as if they used one method. The labels report change from baseline or difference from placebo, in different populations.
• Ignoring the stop instruction. The Wegovy label says to discontinue for a sustained increase; do not decide that alone, but do raise it.
• Assuming a rising pulse is always the drug. Dehydration, illness and stimulants are common alternative explanations.

Questions people ask

Medical disclaimer. This article is informational, was prepared by the GLP-1.Reviews editorial team from the public sources listed above, and is not medical advice. Label wording can change; confirm the instructions for your product with the Medication Guide that came with it. Talk to your prescriber or pharmacist about your own treatment, and see our medical disclaimer and editorial standards.

Next StepRead Our Full GLP-1 Provider Comparison →See the top-rated providers ranked side by side on price, safety and clinical quality.